Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2475746 | 0.94 | — | — | |
| SCHEMBL30159241 | 0.78 | POLA1 (0.32) | POLA1 | |
| SCHEMBL27578070 | 0.78 | POLA1 (0.38) | POLA1GAA | |
| SCHEMBL6276544 | 0.76 | POLA1 (0.47) | POLA1GAA | |
| SCHEMBL10875328 | 0.76 | POLA1 (0.47) | POLA1GAA | |
| SCHEMBL31408912 | 0.74 | — | — | |
| SCHEMBL18606584 | 0.73 | GBA2 (0.31) | POLA1GAA | |
| SCHEMBL11613185 | 0.72 | — | — | |
| SCHEMBL2975191 | 0.72 | POLA1 (0.39) | POLA1 | |
| SCHEMBL30723201 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10463623-B2 | Compositions exhibiting delayed transit through the gastrointestinal tract | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2019-11-05 | — | — | US | claimed |
| EP-2346351-B1 | COMPOSITIONS EXHIBITING DELAYED TRANSIT THROUGH THE GASTROINTESTINAL TRACT | RUBICON RES PRIVATE LIMITED (IN) | 2019-07-03 | — | — | EP | claimed |
| US-20110229569-A1 | COMPOSITIONS EXHIBITING DELAYED TRANSIT THROUGH THE GASTROINTESTINAL TRACT | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2011-09-22 | — | — | US | claimed |
| EP-2346351-A2 | COMPOSITIONS EXHIBITING DELAYED TRANSIT THROUGH THE GASTROINTESTINAL TRACT | Rubicon Research Private Limited (IN) | 2011-07-27 | — | — | EP | claimed |
| WO-2010038237-A2 | COMPOSITIONS EXHIBITING DELAYED TRANSIT THROUGH THE GASTROINTESTINAL TRACT | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2010-04-08 | — | — | WO | claimed |
| US-12377194-B2 | JAB1 inhibitory compositions for ossification and methods related thereto | EMORY UNIVERSITY (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250059512-A1 | TISSUE PROCESSING APPARATUS AND METHOD FOR INFUSING BIOACTIVE AGENTS INTO TISSUE | WARSAW ORTHOPEDIC, INC (US) | 2025-02-20 | — | — | US | disclosed |
| US-12134783-B2 | Tissue processing apparatus and method for infusing bioactive agents into tissue | WARSAW ORTHOPEDIC, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| US-11844802-B2 | Compounds and compositions for ossification and methods related thereto | EMORY UNIVERSITY (US) | 2023-12-19 | — | — | US | disclosed |
| EP-3368095-B1 | BONE VOID FILLER HAVING SUSTAINED THERAPEUTIC AGENT RELEASE | WARSAW ORTHOPEDIC INC (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-3367974-B1 | BONE VOID FILLER HAVING CALCIUM COATINGS | WARSAW ORTHOPEDIC INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20230225973-A1 | MULTI-LAYERED MEDICAMENT FOR INHALATION | MYLAN PHARMA UK LIMITED (GB) | 2023-07-20 | — | — | US | disclosed |
| EP-1040051-A1 | BLISTER PACK | AstraZeneca AB (SE) | 2000-10-04 | — | — | EP | disclosed |
| EP-0981335-A1 | AN ENTERIC COATED ORAL DOSAGE FORM COMPRISING SODIUM AMOXYCILLIN | Astra Aktiebolag (publ) (SE) | 2000-03-01 | — | — | EP | disclosed |
| US-6024222-A | Blister pack | ASTRA AKTIEBOLAG (SE) | 2000-02-15 | — | — | US | disclosed |
| WO-1998040054-A1 | AN ENTERIC COATED ORAL DOSAGE FORM COMPRISING SODIUM AMOXYCILLIN | ASTRA AKTIEBOLAG (PUBL) (SE) | 1998-09-17 | — | — | WO | disclosed |
| WO-1998000351-A1 | BLISTER PACK | ASTRA AKTIEBOLAG (SE) | 1998-01-08 | — | — | WO | disclosed |
| EP-0754061-A1 | NEW ORAL PHARMACEUTICAL DOSAGE FORM | Astra Aktiebolag (SE) | 1997-01-22 | — | — | EP | disclosed |
| WO-1996024375-A1 | NEW ORAL PHARMACEUTICAL DOSAGE FORM | ASTRA AKTIEBOLAG (SE) | 1996-08-15 | — | — | WO | disclosed |
| WO-1994000112-A1 | AN ORAL FORMULATION FOR GASTRIC ANTIBACTERIAL TREATMENT AS WELL AS A PROCESS THEREOF AND THE USE | ASTRA AKTIEBOLAG (SE) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11844802-B2 | Compounds and compositions for ossification and methods related thereto | BMP2, SOST, BMP4 | POLA1 3364/4885GAA 3020/4885 |
| US-20230225973-A1 | MULTI-LAYERED MEDICAMENT FOR INHALATION | NDUFB5, NDUFB7, NDUFB8 | POLA1 1449/4885GAA 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.